Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from NICE

HRT should be the 'first-line' therapy for menopause, new UK guidance confirms

The new guidance comes after a controversial draft last year suggested CBT could be on par with HRT for treating menopause symptoms

Woman & Home

HRT should be offered as first-line treatment for menopause, says Nice

Guidelines for England and Wales address criticism of earlier draft advising CBT ‘alongside or as an alternative’ to HRT

The Guardian - UK

Women with menopause symptoms ‘should be offered HRT as first treatment’

The National Institute for Health and Care Excellence announced the changes

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Alzheimer’s treatment donanemab is not a ‘miracle drug’ – not providing it on the NHS is the right choice

There was frustration in some corners of the media when it was announced that a new drug to slow the progression of Alzheimer’s was not going to be made available on the NHS.

The Conversation

Hundreds of blood cancer patients to benefit from new treatment

Elranatamab, an injection that treats myeloma, has been recommended for NHS use by the National Institute for Health and Care Excellence.

Evening Standard

Hundreds of blood cancer patients to benefit from new Pfizer treatment

Myeloma affects 24,000 people a year in the UK

The Independent UK

3 Tech Stocks With Massive Analyst Price Target Upsides

The tech market is well-positioned for significant growth thanks to the growing adoption of emerging technologies like AI, ML, cloud computing, and ERP. Therefore, it could be wise to invest in top tech stocks NICE Ltd. (NICE), LiveRamp Holdings (RAMP), and TaskUs (TASK) with massive analyst price target upsides. Read…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Alzheimer’s drug approved in the UK, but it won’t be available on the NHS – here’s why

The UK’s drugs regulator – the MHRA – has approved the Alzheimer’s drug donanemab, but it won’t be available on the NHS.

The Conversation

Which disease-modifying Alzheimer’s drugs are the most promising?

Many drugs in development aim to delay, slow or reverse symptoms, but which are causing the biggest stir?

The Guardian - UK

Tens of thousands of UK dementia patients to be enrolled in clinical trials

News of the £20m scheme comes as new drug for Alzheimer’s was rejected for use on NHS in England

The Guardian - UK

UK regulator approves second Alzheimer's drug in months but government won't pay for it

Britain’s drug regulator approved the Alzheimer’s drug Kisunla on Wednesday, but the government won’t be paying for it after an independent watchdog agency said the treatment isn’t worth the cost to taxpayers

The Independent UK

New Alzheimer’s drug rejected for NHS use – because it’s not worth the money

Alzheimer’ patients in UK left behind over regulator’s decision to reject use of new drugs

The Independent UK

Alzheimer's 'wonder drug' Donanemab blocked for use on NHS over cost concerns

Campaigners say decision is ‘frustrating setback’ for people living with disease

Evening Standard

Alzheimer’s drug rejected for widespread use by NHS spending watchdog

Donanemab is a so-called disease-modifying treatment.

Evening Standard

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Donanemab: What is the new Alzheimer’s drug rejected for use on the NHS

Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in research

Evening Standard

Donanemab – what we know about the latest Alzheimer’s drug

The drug is one of the new ‘disease modifying’ treatments for Alzheimer’s disease.

The Independent UK

Decision expected on new Alzheimer’s treatment

The drug is one of the new ‘disease modifying’ treatments for Alzheimer’s disease.

The Guardian - UK

A dualistic view of illness doesn’t help those with ME/CFS

Letters: Peter White, Trudie Chalder and Michael Sharpe, and Dr Jake Hollis, respond to an article by George Monbiot

Get all your
news in one place.

100’s of premium titles.
One news app.

FourFourTwo

Arsenal legend makes true feelings felt on Manchester United owners

The former Arsenal man has revealed his thoughts on the Manchester United owners following his time under INEOS

The Guardian - UK

NHS in England given go-ahead for AI scans to help detect bone fractures

X-ray add-on at estimated £1 a scan aimed at reducing missed diagnoses in initial assessment

Woman & Home

I tried CBT for menopause - here are my honest thoughts

CBT for menopause is one of the recommended alternatives to HRT. Here's what happened when writer Laura Williams was prescribed 6 weeks for her symptoms

The National (Scotland)

Chance for Scotland to lead with Alzheimer’s treatment

SCOTLAND has a “golden opportunity” to lead the way in dementia care if the NHS is given the go-ahead to use a new kind of treatment.

The Guardian - UK

The Ineos Effect: hit and miss as Jim Ratcliffe’s tentacles have gone global

Ratcliffe has built an empire of assets across different sports but his teams have enjoyed varying degrees of success

The Independent UK

Lyme disease: What are the symptoms and how can it be treated?

Lyme Disease UK has warned that the disease is on the rise in the UK

The Conversation

Mounjaro will soon be available as a weight loss treatment on the NHS – here’s what that means for patients

The weight loss jab Mounjaro will soon be made available to nearly a quarter of a million NHS patients, according to proposals made by the National Institute for Health and Care Excellence (Nice). Previously, it was only available on the NHS for patients with diabetes.

1 … 9 10 11 12

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Alzheimer Research UK

146 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.